Gene · 4301
AFDN: afadin, adherens junction formation factor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. AFDN: afadin, adherens junction formation factor. Genes, record 4301. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4301
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P55196 | Afadin | 1,824 | 6 | Ensembl, GeneID, HGNC |
Source UniProt
Patents27
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 54454 | P55196 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 15100 | P55196 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 15301 | P55196 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 15100 | P55196 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 15301 | P55196 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 15301 | P55196 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 15140 | P55196 | Espacenet |
| US 12023385 B2 | 2024-07-02 | 44 | P55196 | Espacenet |
| EP 4119552 A1 | 2023-01-18 | 58 | P55196 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 54082 | P55196 | Espacenet |
1 to 10 of 27
See all 27 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,132
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | AFDN papers | Newest fiscal year |
|---|---|---|---|
| R35GM118096 | Regulating cell fate and shaping the body plan during morphogenesis and their alteration during oncogenesis | 13 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 12 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 9 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 7 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 5 | 2025 |
| R01DK079392 | Intestinal Inflammation: Signaling proteins and the rate of PMN transmigration | 5 | 2025 |
| R01MH071316 | Rac-GEF signaling in dendritic spines | 5 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 4 | 2025 |
| U10CA180886 | COG NCTN Network Group Operations Center - Year 11 STAR Act MCI and PEC Supplement | 4 | 2025 |
1 to 10 of 1,132Source NIH's project files
See all 1,132 nih grantsPapers1,720
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| AF6 orchestrates macrophage polarization via JAK2-STAT3 signaling and supports intestinal regeneration by stimulating stem cell proliferation. | Front Immunol | 2026 | 42404906 | PubTator, text mining | PubMed |
| [Preneoplastic and Neoplastic Small Lymphocytic Proliferations Concurrent with Acute Myeloid Leukemia: A Report of Four Cases]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2026 | 42227422 | PubTator, text mining | PubMed |
| Strength in numbers: Proteins travel as condensates to reinforce cell-cell junctions under stress. | J Cell Biol | 2026 | 42171593 | PubTator, text mining | PubMed |
| p120-catenin downregulation selectively modulates inflammatory susceptibility in eyelid specimens of rosacea. | Exp Eye Res | 2026 | 42114612 | PubTator, text mining | PubMed |
| All-trans retinoic acid combined with the VAH regimen for EVI1-positive acute myeloid leukemia: a case report with a brief literature review. | Front Oncol | 2026 | 42063737 | PubTator, text mining | PubMed |
| Adherens junctions balance stability and motility: from cell morphogenesis to neural tissue patterning. | Biol Chem | 2026 | 41955739 | PubTator, text mining | PubMed |
| Edge-vertex flow enables rapid adhesion reinforcement under tension. | J Cell Biol | 2026 | 41955013 | PubTator, text mining | PubMed |
| Circular and Long Non-Coding RNAs in Cancer Metabolism: Dual Perspective of Biomarkers and Therapeutic Targets. | Noncoding RNA | 2026 | 41874139 | PubTator, text mining | PubMed |
| Mechanisms of active wetting and fluidification in epithelial cell collectives. | Nat Mater | 2026 | 41872301 | PubTator, text mining | PubMed |
| Interplay between flaviviruses and the interferon response: mechanisms of immune evasion and therapeutic implications. | Front Pharmacol | 2026 | 41788799 | PubTator, text mining | PubMed |
1 to 10 of 1,720
See all 1,720 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4301
GET https://conductscience.org/api/genes/v1/4301/patents?page=2